Sanofi (NASDAQ:SNY) Position Trimmed by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,760 shares of the company’s stock after selling 335 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Sanofi were worth $326,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi during the 3rd quarter valued at about $29,000. Concord Wealth Partners increased its position in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Fortitude Family Office LLC increased its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the period. Sunbelt Securities Inc. increased its position in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Finally, Versant Capital Management Inc bought a new stake in Sanofi in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Up 1.9 %

Shares of SNY opened at $51.69 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market capitalization of $131.18 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.24 and a beta of 0.57. The stock’s fifty day simple moving average is $48.46 and its 200-day simple moving average is $52.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm posted $2.55 earnings per share. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts predict that Sanofi will post 3.94 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.